ArticleCell death & disease2025
Novel role of L-2-HG in regulating HIF1A signaling pathway and iron death resistance in renal cancer brain metastasis.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Elevated ferroptosis is associated with elevated T cells in patients with heat stroke.Molecular biology reports · 2026Article
- Lactylation-regulated ferroptosis: mechanisms, disease associations, and therapeutic strategies.Archives of pharmacal research · 2026Review
- Crosstalk BetweenCancers · 2026Review
- Lactylation in urological malignancies: emerging mechanisms and therapeutic direction.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-2-hydroxyglutarate (L-2-HG) functions as a metabolite implicated in the progression of various tumors. HIF1A, a central regulator of the hypoxic response, is known to be regulated by several metabolites. This study aims to elucidate whether L-2-HG regulates the function of HIF1A through histone lactylation modification, thereby contributing to brain metastasis in renal cell carcinoma (RCC). A mouse model of RCC brain metastasis was constructed, and high-throughput metabolomics, transcriptomics, and proteomics sequencing analyses were conducted. Bioinformatics analysis revealed that L-2-HG enhanced HIF1A expression by promoting histone lactylation modification, which suppressed ferroptosis and facilitated RCC brain metastasis. In vitro cellular experiments were conducted, including cell treatment, transfection, chromatin immunoprecipitation (ChIP), malignant phenotype detection assays, Western blotting, and RT-qPCR. The results showed that L-2-HG increased the lactylation modification of HIF1A and enhanced the resistance of renal cancer cells to ferroptosis, thereby increasing cell proliferation, migration, and invasion. In vivo experiments using a nude mouse lung metastasis model demonstrated the mechanism through which L-2-HG promoted RCC brain metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.